TEVA.N Teva Pharmaceutical Industries Limited Sponsored ADR

Teva to Present at the Citi 2016 Global Healthcare Conference

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the Citi 2016 Global Healthcare Conference.

Erez Vigodman will present on Thursday, December 8, 2016 at 10:15 AM EST.

What:

            Teva Presentation at the Citi 2016 Global Healthcare Conference
 

Who:

Erez Vigodman, President and CEO,
Teva Pharmaceutical Industries Ltd.
 

When:

Thursday, December 8, 2016
 

Where:

www.ir.tevapharm.com

 

How:

Live over the Internet – log on to the Web at the address above and register for the
event (approximately 10 minutes before). An archive of the webcast will be available
on Teva’s website.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2015 were $19.7 billion. For more information, visit www.tevapharm.com.

EN
07/12/2016

Underlying

Reports on Teva Pharmaceutical Industries Limited Sponsored ADR

 PRESS RELEASE

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Applic...

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations1Teva is committed to advancing this innovative treat...

 PRESS RELEASE

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated cli...

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of inductionDuvakitug was well tolerated and safety was consistent with the induction studyFindings reinforce the potential of duvakitug which is in ongoing phase 3 programs in UC and CD Teva will hold an investor call and live webcast today, Tuesday, February 17, 2026, at 8:00 a.m. ...

Si Yong Ng
  • Si Yong Ng

Lucror Analytics - Convertibles Brief

In today's Convertibles Brief publication we comment on developments of the following high yield issuers: Teva

Haidje Rustau ... (+5)
  • Haidje Rustau
  • Jayanth Kandalam
  • Peter Low
  • Si Yong Ng
  • Tanvi Arora

Lucror Analytics - Morning Views Europe

In today's Morning Views publication we comment on developments of the following high yield issuers: Virgin Media O2, Italmatch Chemicals, Trivium, Air Baltic, Travelodge, Teva

 PRESS RELEASE

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth ...

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding Japan BV, revenues increased 5% YoY in LC.Key Innovative brands continued to drive growth and provide value for patients, with 2025 revenues surpassing $3 billion, +35% YoY in LC: AUSTEDO® global revenues of $2.26 bill...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch